Shares of GlaxoSmithKline plc (NYSE:GSK) have been assigned an average rating of “Hold” from the twenty-one analysts that are currently covering the company, MarketBeat Ratings reports. Three investment analysts have rated the stock with a sell rating, ten have issued a hold rating and six have given a buy rating to the company. The average 12 month price target among brokers that have covered the stock in the last year is $37.71.

GSK has been the subject of several research analyst reports. BidaskClub raised GlaxoSmithKline from a “strong sell” rating to a “sell” rating in a research note on Friday, August 25th. Argus reaffirmed a “buy” rating and set a $50.00 target price on shares of GlaxoSmithKline in a research note on Thursday, August 31st. Morgan Stanley downgraded GlaxoSmithKline from an “equal weight” rating to an “underweight” rating in a research note on Friday, September 8th. J P Morgan Chase & Co reaffirmed a “neutral” rating on shares of GlaxoSmithKline in a research note on Thursday, September 14th. Finally, Zacks Investment Research raised GlaxoSmithKline from a “hold” rating to a “buy” rating and set a $46.00 target price for the company in a research note on Wednesday, October 18th.

Shares of GlaxoSmithKline (GSK) traded up $0.14 during mid-day trading on Monday, hitting $35.31. The stock had a trading volume of 3,844,613 shares, compared to its average volume of 3,526,148. The company has a current ratio of 0.64, a quick ratio of 0.44 and a debt-to-equity ratio of 2.96. The firm has a market cap of $86,495.23, a P/E ratio of 12.47, a price-to-earnings-growth ratio of 1.95 and a beta of 0.98. GlaxoSmithKline has a twelve month low of $34.52 and a twelve month high of $44.53.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, January 11th. Investors of record on Friday, November 10th will be paid a $0.5037 dividend. This is an increase from GlaxoSmithKline’s previous quarterly dividend of $0.49. This represents a $2.01 annualized dividend and a yield of 5.71%. The ex-dividend date is Thursday, November 9th. GlaxoSmithKline’s dividend payout ratio is currently 163.12%.

In other news, major shareholder Plc Glaxosmithkline acquired 428,571 shares of GlaxoSmithKline stock in a transaction that occurred on Monday, November 6th. The stock was purchased at an average cost of $14.00 per share, with a total value of $5,999,994.00. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. 10.00% of the stock is currently owned by corporate insiders.

Several institutional investors and hedge funds have recently modified their holdings of the business. Shelton Capital Management increased its stake in shares of GlaxoSmithKline by 73.5% in the 3rd quarter. Shelton Capital Management now owns 28,331 shares of the pharmaceutical company’s stock worth $1,150,000 after acquiring an additional 12,000 shares during the last quarter. Steward Partners Investment Advisory LLC purchased a new position in shares of GlaxoSmithKline during the 3rd quarter worth $328,000. Belpointe Asset Management LLC purchased a new position in shares of GlaxoSmithKline during the 3rd quarter worth $204,000. Wealthcare Advisory Partners LLC grew its holdings in shares of GlaxoSmithKline by 1,982.8% during the 3rd quarter. Wealthcare Advisory Partners LLC now owns 3,520 shares of the pharmaceutical company’s stock worth $143,000 after purchasing an additional 3,351 shares during the period. Finally, Sterling Capital Management LLC grew its holdings in shares of GlaxoSmithKline by 46.1% during the 3rd quarter. Sterling Capital Management LLC now owns 12,560 shares of the pharmaceutical company’s stock worth $510,000 after purchasing an additional 3,963 shares during the period. 9.83% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This piece was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/12/11/glaxosmithkline-plc-gsk-receives-consensus-recommendation-of-hold-from-analysts.html.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.